The notices it replaced
- Reissues: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 2 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 4 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-18-575.
Who won it before
910 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $285,463,250 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]67
- Special Emphasis Panel[ZRG1 OTC-T (10)]56
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 ETTN-G (12)]44
- Special Emphasis Panel[ZRG1 RPHB-C (10)]33
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC9
- MEDOSOME BIOTEC, LLC7
- FIREBIRD BIOMOLECULAR SCIENCES, LLC6
- L2 DIAGNOSTICS, LLC6
- MICROBIOTIX, INC6
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy1R41NS116784-01 | KHANNA, RAJESH | REGULONIX, LLC, NY | $341,527 | ZRG1 |
| 2019 | Medications for Synthetic Cannabinoid Abuse1R41DA044048-01A1 | MAKRIYANNIS, ALEXANDROS | PAFOSPHARMA, LLC, MA | $225,000 | ZRG1 |
| 2018 | Testing a male oral contraceptive targeting Eppin2R42HD084077-02 · under PA-16-303 | ORAND, MICHAEL GENE | EPPIN PHARMA, INC., NC | $1,097,562 | ZRG1 |
| 2018 | Automated Object Contouring Methods & Software for Radiotherapy Planning2R42CA199735-02 | OWENS, STEVEUDUPA, JAYARAM K | QUANTITATIVE RADIOLOGY SOLUTIONS, LLC, PA | $1,057,846 | ZRG1 |
| 2018 | Development of a protein drug for pancreatic cancer treatment2R42CA217482-02 | LIU, ZHI-REN | PRODA BIOTECH, LLC, GA | $999,780 | ZRG1 |
| 2018 | Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer2R42CA203456-02A1 | HAILEMICHAEL, YAREDMARATHI, UPENDRAWOODSIDE, DARREN G | 7 HILLS PHARMA, LLC, TX | $999,501 | ZRG1 |
| 2018 | Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis2R42AI120751-02A1 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $998,500 | ZRG1 |
| 2018 | Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma2R42CA213488-02 | MARCOUX, FRANK W. | LEUKOGENE THERAPEUTICS, INC., SC | $984,129 | ZRG1 |
| 2018 | Testing and Commercialization of a Superior Device to Maintain Perioperative Normothermia In Anesthetized Patients2R42GM119871-02 | DILLER, KENNETH R.SESSLER, DANIEL I | MERCURY BIOMED, LLC, OH | $978,894 | ZRG1 |
| 2018 | Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.1R42HL144342-01 | CHIRIVA-INTERNATI, MAURIZIOTAFFET, GEORGE E | KIROMIC, INC., TX | $850,531 | ZRG1 |
| 2018 | The nGoggle: A portable brain-based device for assessment of visual function deficits2R42EY027651-02 | MEDEIROS, FELIPETSENG, HENRYZAO, JOHN KAR-KIN | NGOGGLE, INC., CA | $849,367 | ZRG1 |
| 2018 | Novel SCD1 inhibitors for treatment of cancer2R42CA195946-02A1 | COPLAND, JOHN A.HAYES, KAREN | MODULATION THERAPEUTICS, INC., WV | $763,181 | ZRG1 |
| 2018 | Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes2R42HL127901-02A1 · under PA-16-303 | BETT, GLENNA C L | CYTOCYBERNETICS, INC., NY | $748,969 | ZRG1 |
| 2018 | Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses2R42CA192600-02 | CAI, WENLIWU, YIN | IQ MEDICAL IMAGING, LLC, MA | $740,417 | ZRG1 |
| 2018 | MDCT Quantification of hepatic tumor viability for assessment of cancer therapy2R42CA189637-02A1 | CAI, WENLIWU, YIN | IQ MEDICAL IMAGING, LLC, MA | $726,042 | ZRG1 |
| 2018 | Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)2R42AA025863-02 | YANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $666,670 | ZRG1 |
| 2018 | Immuno-CometChip for Human Skin Basal Cell Genotoxicity Testing2R42ES026908-02 · under PA-16-303 | GEORGE, JAYROSENTHAL, DEANSYKORA, PETER | AMELIA TECHNOLOGIES, LLC, DC | $666,400 | ZRG1 |
| 2018 | Validation of Novel Therapeutic Approach for Leptomeningeal Metastases2R42CA206744-02A1 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $665,919 | ZRG1 |
| 2018 | Measuring Bladder Permeability with MRI Using a Novel Contrast Agent Formulation2R42DK108397-02A1 | KAUFMAN, JONATHAN H | LIPELLA PHARMACEUTICALS, INC., PA | $656,417 | ZRG1 |
| 2018 | Create Ultralong DNA Constructs in One Assembly Step2R42GM119494-02 | BENNER, STEVEN AHOSHIKA, SHUICHI | FIREBIRD BIOMOLECULAR SCIENCES, LLC, FL | $648,409 | ZRG1 |
| 2018 | Novel Indication for Myeloid Progenitor Use: Induction of Tolerance in Solid Organ Transplantation2R42AI108016-02A1 · under PA-16-303 | DOMEN, ADRIANUS G.W.PANUGANTI, SWAPNA | CELLERANT THERAPEUTICS, INC., CA | $573,592 | ZRG1 |
| 2018 | Development of Nasal IGF-1 as a Migraine Therapeutic1R43NS108824-01 | KRAIG, RICHARD PZHANG, YUAN | SEURAT THERAPEUTICS, INC., IL | $509,720 | ZRG1 |
| 2018 | A software tool for objective identification of concussion-related vision disorders using a novel eye-tracking device1R41NS103698-01A1 · under PA-16-303 | MASTER, CHRISTINA L. | OCULOGICA, INC., NY | $503,162 | ZRG1 |
| 2018 | Automated Assessment of Leptomeningeal Collaterals on CT Angiograms2R42NS086295-02A1 | AYLWARD, STEPHEN RLEE, YUEH ZNIETHAMMER, MARC | KITWARE, INC., NY | $489,999 | ZRG1 |
| 2018 | Development of a novel Balloon Occlusion Sheath for Stroke (BOSS)1R41NS103670-01A1 | KALLMES, DAVID F | MARBLEHEAD MEDICAL, LLC, MN | $478,694 | ZRG1 |
| 2018 | Protein ProFiler Microfluidic Electrophoresis System for Proteomics1R41GM130206-01 | WIKTOROWICZ, JOHN EDWARD | INNOVAREGI, LLC, CA | $477,539 | ZRG1 |
| 2018 | Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke1R41NS105263-01A1 | GRANDE, ANDREW WLEE, JI EUN | SERINA THERAPEUTICS, INC., CA | $385,923 | ZRG1 |
| 2018 | Product for sensitive imaging of cells in vivo1R41EB023761-01A1 | O'HANLON, CHARLES F | CELSENSE, INC., PA | $340,802 | ZRG1 |
| 2018 | Nucleobase aminosugars with reduced ototoxicity1R41DC016257-01A1 · under PA-16-303 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $305,919 | ZRG1 |
| 2018 | Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse1R41DA046266-01 | ZACZEK, ROBERT | NEUROP, INC., GA | $301,303 | ZRG1 |
| 2018 | In vitro and in vivo evaluation of elephant p53 (EP53) protein nanoparticles for pediatric osteosarcoma1R41CA221653-01A1 | SCHIFFMAN, JOSHUA DAVID | PEEL THERAPEUTICS, INC., UT | $300,465 | ZRG1 |
| 2018 | Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD1R42EY029625-01 | HANDA, JAMES TKOCAB, ANDREW JOSEPH | ONL THERAPEUTICS, INC., MI | $300,202 | ZRG1 |
| 2018 | Trigriluzole for the Treatment of Cocaine Addiction1R41DA047169-01 | RAWLS, SCOTT M. | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,002 | ZRG1 |
| 2018 | Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery1R41CA228841-01A1 | YANG, CHUN | CAVATAR, LLC, CA | $300,001 | ZRG1 |
| 2018 | Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections1R41AI136072-01 · under PA-16-303 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $300,000 | ZRG1 |
| 2018 | Discovery of Zika virus therapeutics using a replicon assay1R41AI136126-01 · under PA-16-303 | BOWLIN, TERRY L. | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2018 | Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO1001R41CA217551-01A1 · under PA-16-303 | CHEN, THOMAS C.WANG , WEIJUN | NEONC TECHNOLOGIES, INC., CA | $300,000 | ZRG1 |
| 2018 | Multicolor Photoacoustic Malaria Detector1R41AI138690-01 | SUEN, JAMESZHAROV, VLADIMIR P | CYTOASTRA, LLC, AR | $300,000 | ZRG1 |
| 2018 | DNA Quadruplex Control of hTERT Transcription: A New Therapy for Taxotere Resistant Prostate Cancer1R41CA224497-01A1 | HURLEY, LAURENCE H.MIRANTI, CYNTHIA K | REGLAGENE, LLC, AZ | $300,000 | ZRG1 |
| 2018 | Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment1R41CA221595-01A1 | SHIH, WEI-HENG | AQD LIFE SCIENCES, LLC, PA | $300,000 | ZRG1 |
| 2018 | Targeting glioblastoma stem-like cells with custom-designed viral vectors1R42CA228875-01 | TRAN, DAVID DWARRINGTON, KENNETH HZOLOTUKHIN, SERGEI | LACERTA THERAPEUTICS, INC., FL | $300,000 | ZRG1 |
| 2018 | Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses1R41AI138630-01A1 | HARTY, RONALD N | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2018 | Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae1R41AI136233-01 · under PA-16-303 | FELDMAN, MARIO | VAXNEWMO, LLC, MO | $299,999 | ZRG1 |
| 2018 | Development of GPER agonists as Cancer Therapeutics1R41CA228695-01 | RIDKY, TODD W | LINNAEUS THERAPEUTICS, LLC, PA | $299,998 | ZRG1 |
| 2018 | Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML1R41CA224830-01 · under PA-16-303 | FRETT, BRENDAN ANDREWGUZMAN, MONICA LLI, HONG YU | SYNACTIX PHARMACEUTICALS, INC., AZ | $299,975 | ZRG1 |
| 2018 | Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis1R41HL142357-01 | LARSON, JEFFREY LEROY | ITERION THERAPEUTICS INC., TX | $299,974 | ZRG1 |
| 2018 | Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta1R41CA224504-01A1 | SETH, PREM | MULTIVIR, INC., TX | $299,956 | ZRG1 |
| 2018 | Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence1R41DA044898-01 · under PA-16-303 | BRENNEMAN, DOUGLAS ERICWARD, SARA J | KANNALIFE SCIENCES, INC., NY | $299,916 | ZRG1 |
| 2018 | Development of a Spirulina-based oral malaria vaccine1R41AI138623-01A1 | MURPHY, SEAN C | LUMEN BIOSCIENCE, INC., WA | $299,904 | ZRG1 |
| 2018 | Rapid development of a Zika-specific diagnostic test1R41AI138720-01 | WATKINS, DAVID I | Z-QUICK, LLC, FL | $299,890 | ZRG1 |
| 2018 | Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks1R41AI131840-01A1 · under PA-16-303 | ELSHERIF, LAILA | EPICYPHER, INC., NC | $299,751 | ZRG1 |
| 2018 | Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity1R41CA232779-01 | MORALES, GUILLERMO A | SIGNALRX PHARMACEUTICALS, INC., GA | $299,738 | ZRG1 |
| 2018 | Graft-protective properties of LGM2605 in Lung Transplantation1R41HL142384-01A1 | CHRISTOFIDOU-SOLOMIDOU, MELPOSIELECKI, THAIS MOTRIA | LIGNAMED, LLC, PA | $299,599 | ZRG1 |
| 2018 | Development of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)1R41CA221466-01A1 | CHAN, WING C.IQBAL, JAVEEDMORRIS, STEPHAN WADE | HEALTHCHART, LLC, TN | $299,397 | ZRG1 |
| 2018 | An innovative WGS platform for discovery, annotation, and interpretation of all forms of human genetic variation.1R41HG010126-01A1 | PEDERSEN, BRENT | BASE2 GENOMICS, LLC, UT | $299,281 | ZRG1 |
| 2018 | Novel therapeutic monoclonal antibody targeting SP-R210 isoforms to prevent influenza disease progression and expedite resolution of comorbidities1R41AI136294-01A1 | AGRAWAL, ANDY | RESPANA THERAPEUTICS, INC., PA | $298,498 | ZRG1 |
| 2018 | A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy1R41CA228622-01 | NGUYEN, HIEN-ANH | ENZYME BY DESIGN, INC., IL | $298,305 | ZRG1 |
| 2018 | Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)1R41EY028839-01 · under PA-16-303 | COOK, JASON | NANOHYBRIDS, INC., TX | $297,786 | ZRG1 |
| 2018 | Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia1R42AI136065-01A1 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $297,455 | ZRG1 |
| 2018 | Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections1R41AI140782-01 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $295,171 | ZRG1 |
| 2018 | Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation1R41CA224520-01A1 | KRUPNICK, ALEXANDER S. | COURIER THERAPEUTICS, INC., TX | $288,105 | ZRG1 |
| 2018 | SuperGAGs for Intravesicular Treatment of Interstitial Cystitis1R43DK116356-01A1 | HURST, ROBERT EVAN | GLYCOLOGIX, LLC, MA | $287,615 | ZRG1 |
| 2018 | CCN3-derrived peptides to treat liver injury1R41DK116448-01A1 | RISER, BRUCE L | BLR BIO, LLC, WI | $285,690 | ZRG1 |
| 2018 | Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury1R41HL135945-01A1 · under PA-16-303 | BOGATCHEVA, NATALIACLAUSS, MATTHIAS | ALLINAIRE THERAPEUTICS, LLC, OH | $281,155 | ZRG1 |
| 2018 | A platform for coupling chromatin profiling with single cell transcriptomics1R43HG010128-01 | COLE, RUSSELL H | SCRIBE BIOSCIENCES, INC., CA | $280,000 | ZRG1 |
| 2018 | Microfluidic CAR-T Cell Processing Device1R42CA228616-01 | CIVIN, CURT ISTURM, JAMES CWARD, TONY | GPB SCIENTIFIC, INC., VA | $279,969 | ZRG1 |
| 2018 | Targeting the sphingolipid pathway for the R&D of new antifungals1R41AI134428-01A1 | DEL POETA, MAURIZIO | MICRORID TECHNOLOGIES, INC., NY | $279,393 | ZRG1 |
| 2018 | Advancing Formulation of STING agonist for Universal Flu Vaccine1R41AI140795-01 | AINSLIE, KRISTY MGOYAL, ANIL KUMAR | IMMVENTION THERAPEUTIX, INC., NC | $277,218 | ZRG1 |
| 2018 | A cell-free, high-throughput screening service for accelerated GPCR ligand discovery1R41GM126674-01 · under PA-16-303 | SONDEK, JOHN E | KXT, BIO INC., NC | $276,339 | ZRG1 |
| 2018 | Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS1R41CA224888-01A1 | ONOFREY, JOHN AARON | ZMK MEDICAL TECHNOLOGIES, D/B/A EIGEN, CA | $265,877 | ZRG1 |
| 2018 | A Novel Treatment for Acetominophen-Induced Liver Injury1R41DK117760-01A1 | RINCON, MERCEDES | MITOTHERAPEUTIX, LLC, CT | $264,238 | ZRG1 |
| 2018 | Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury1R42NS105238-01 · under PA-16-303 | HUETTEMANN, MAIKSANDERSON, THOMAS HUDSON | MITOVATION, INC., MI | $248,042 | ZRG1 |
| 2018 | Cuff Electrodes with Soft Wire Electrical Leads1R41NS108865-01 | CLAPSADDLE, BRADY JOHN | TDA RESEARCH, INC., CO | $246,541 | ZRG1 |
| 2018 | Myocardial delivery of MMP inhibiting hydrogels1R41HL140645-01A1 | BURDICK, JASON A | PROHIBIX, LLC, PA | $245,772 | ZRG1 |
| 2018 | Software and services to advance does-response modeling in chemical risk assessment1R41TR002567-01A1 | SHAO, KAN | KS AND ASSOCIATES, LLC, IN | $245,130 | ZRG1 |
| 2018 | Inert Coating for Cerebral Shunts to Eliminate Clogging1R41NS103704-01A1 | JONES, ANDREW K | CERULEAN SCIENTIFIC INC., PA | $245,001 | ZRG1 |
| 2018 | Selection and Development of a Lead Biologic for Treating Mitochondrial Disorders1R41AG059530-01 | HILL, R BLAKE | CYTEGEN CORPORATION, CO | $241,568 | ZRG1 |
| 2018 | Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate1R41DK115317-01A1 | COLEMAN, MICHAEL ELMO | THERATOME BIO, INC., IN | $238,130 | ZRG1 |
| 2018 | A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE1R41AI138764-01 | BENMOHAMED, LBACHIR | SUNOMIX THERAPEUTICS, CA | $235,980 | ZRG1 |
| 2018 | A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy1R41DK117684-01 | DAVIES, KELVIN PSHARP, DAVID JAMES | MICROCURES, INC., CA | $234,898 | ZRG1 |
| 2018 | Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors1R41DA045398-01 · under PA-16-303 | VASSOLER, FAIR M | WEINBERG MEDICAL PHYSICS, LLC, MD | $229,701 | ZRG1 |
| 2018 | Topical selective T-type blockers for the treatment of neuropathic pain1R41NS105304-01A1 | ASTRUC DIAZ, FANNY | DERMAXON, LLC, MT | $228,479 | ZRG1 |
| 2018 | MRI-compatible and integrated devices for simultaneous neural recording, stimulation, imaging1R41NS105298-01 · under PA-16-303 | IRAZOQUI, PEDRO | MR-LINK, LLC, IN | $228,325 | ZRG1 |
| 2018 | Development of a User-friendly Bayesian Software Package: Proof of Concept1R41GM126615-01A1 | WENDELBOE, AARON M | BAYESIC TECHNOLOGIES, LLC, OK | $228,095 | ZRG1 |
| 2018 | CN-105 Improves Functional Outcome After Intracranial Hemorrhage1R41NS108821-01 | FREMEAU, ROBERT T | AEGISCN, LLC, NC | $227,501 | ZRG1 |
| 2018 | Noninvasive Seizure Screening in Preclinical Models of Epilepsy1R41NS107148-01 | SUNDERAM, SRIDHAR | SIGNAL SOLUTIONS, LLC, KY | $227,455 | ZRG1 |
| 2018 | Develop novel lutein biomanufacturing in a nonmodel yeast via engineered metabolons and metabolic analyses1R41GM130277-01 | YECHUN, WANG | ARCH INNOTEK, LLC, CT | $226,729 | ZRG1 |
| 2018 | PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis1R42HL140701-01A1 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $225,769 | ZRG1 |
| 2018 | Retinal eye-tracking for the prognosis and monitoring of multiple sclerosis1R41NS100222-01A1 · under PA-16-303 | SHEEHY, CHRISTY KATHLEEN | C. LIGHT TECHNOLOGIES, INC., CA | $225,392 | ZRG1 |
| 2018 | Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing1R41DK119048-01 | GALEN, PETER | HEMEX HEALTH, INC., OR | $225,072 | ZRG1 |
| 2018 | Intravascular molecular-structural NIRF-IVUS imaging of coronary artery disease1R41HL140671-01 · under PA-16-303 | JAFFER, FAROUC AMIN | INTRAVASCULAR IMAGING, INC., MA | $225,000 | ZRG1 |
| 2018 | Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics1R41AI131823-01A1 · under PA-16-303 | POLEJAEVA, IRINA A.SULLIVAN, EDDIE J | SAB CAPRA, LLC, UT | $225,000 | ZRG1 |
| 2018 | Embryonic stem cell high throughput screen accurately reports toxic stress1R41ES028991-01 · under PA-16-303 | ABDULHASAN, MOHAMMEDRAPPOLEE, DANIEL ALLEN | REPRODUCTIVE STRESS; MEASUREMENT, MECHANISMS AND MANAGEMENT, CORPORATION, MI | $225,000 | ZRG1 |
| 2018 | Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.1R41GM126603-01 · under PA-16-303 | RAMPERSAUD, ARFAANWOOD, DAVID W | COLUMBUS NANOWORKS, INC., OH | $225,000 | ZRG1 |
| 2018 | Galectin-1 Protein Therapy for Congenital Muscular Dystrophy1R41AR073696-01 | BURKIN, DEAN J. | STRYKAGEN CORPORATION, NV | $225,000 | ZRG1 |
| 2018 | Theranostic Virtual Reality Headset for Amblyopia1R41EY028466-01A1 | VERSEK, CRAIG | NEUROFIELDZ, INC., MA | $225,000 | ZRG1 |
| 2018 | Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus1R41AR073097-01A1 | WEINSTEIN, JASON | L2 DIAGNOSTICS, LLC, CT | $225,000 | ZRG1 |
| 2018 | A Mobile Tai Chi Platform for Fall Prevention in Older Adults1R42AG059491-01 | BONATO, PAOLOWAYNE, PETER MICHAEL | BIOSENSICS, LLC, MA | $225,000 | ZRG1 |
| 2018 | Optimization of Novel Ryanodine Receptor Modulatory Compounds for Alzheimer's Disease1R41AG055224-01A1 | BUOLAMWINI, JOHN KSTUTZMANN, GRACE | NEUROLUCENT, INC., IL | $225,000 | ZRG1 |
| 2018 | New RSV Vaccines with Improved Safety and Efficacy1R41AI134132-01A1 | KANG, SANG-MOO | ADVAC, LLC, GA | $225,000 | ZRG1 |
| 2018 | Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.1R41NS106999-01A1 | PIOMELLI, DANIELE | ASPIREBIO CORPORATION, CO | $225,000 | ZRG1 |
| 2018 | Cell-free protein synthesis (CFPS) devices with high-yield for synthetic biology1R41GM130205-01 | DAS, CHAMPAK | DASFANH BIOSCIENCES, LLC, FL | $225,000 | ZRG1 |
| 2018 | Astroglial EAAT2 Changes in Live TBI Brain Determined by PET Imaging1R41NS105309-01A1 | GERDES, JOHN MROSI, SUSANNAVANBROCKLIN, HENRY F. | RIO PHARMACEUTICALS, INC., CA | $225,000 | ZRG1 |
| 2018 | Device for Multi-Frequency Oscillatory Ventilation in Adult Patients with the Acute Respiratory Distress Syndrome1R41HL140640-01A1 | KACZKA, DAVID W. | OSCILLAVENT, INC., IA | $225,000 | ZRG1 |
| 2018 | Point of care detection of extracellular vesicles in urine for diagnosis of preeclampsia1R41HD096993-01 | STYBAYEVA, GULNAZ | SERSENSE, INC., MN | $225,000 | ZRG1 |
| 2018 | Development of Drug Delivery Technology for Stem Cell-Based TMJ Regeneration1R41DE028215-01 | CHEN, MOEMBREE, MILDRED CHRISTINE | WNT SCIENTIFIC, LLC, NY | $225,000 | ZRG1 |
| 2018 | Technology for the non-invasive surveilance of post-traumatic compartment syndrome1R41AR074345-01 | LUPTON, ELMER CRUTKOVE, SEWARD B. | MYOLEX, INC., MA | $225,000 | ZRG1 |
| 2018 | A user-friendly microfluidic chip for anti-epileptogenic drug screening1R41NS108895-01 | TAYLOR, ANNE MARION | XONA MICROFLUIDICS, LLC, NC | $225,000 | ZRG1 |
| 2018 | Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure1R41EB028150-01 | BROOME, ANN-MARIE | TOLERAM NANOTECH, LLC, SC | $225,000 | ZRG1 |
| 2018 | Microfluidic diamond NMR sensor1R41GM130239-01 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $225,000 | ZRG1 |
| 2018 | Nanofiber Expanded CD34+ Stem Cells for Osteoporosis Therapy1R41AG057242-01A1 | DAS, HIRANMOY | HNB THERAPEUTICS, LLC, OH | $224,999 | ZRG1 |
| 2018 | KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis1R42MD013412-01 | CHADHA, KAILASH CUNDERWOOD, WILLIE | KAPS BIOTECH, INC., NY | $224,999 | ZRG1 |
| 2018 | Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth1R41HD094622-01 · under PA-16-303 | DAMSKER, JESSE | REVERAGEN BIOPHARMA, INC., MD | $224,998 | ZRG1 |
| 2018 | Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA1R41AI134561-01A1 | EKINS, SEANFREUNDLICH, JOEL STEPHEN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $224,998 | ZRG1 |
| 2018 | Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer1R41CA228854-01 | PAWELETZ, CLOUD PETER | DIGITAL BIOANALYTICS, INC., AZ | $224,998 | ZRG1 |
| 2018 | A universal eye drop adherence monitor to measure and improve adherence to ocular medications1R41EY028807-01 · under PA-16-303 | MANSBERGER, STEVEN LPORTER, JOSE D | UNIVERSAL ADHERENCE, LLC, OR | $224,997 | ZRG1 |
| 2018 | TFEB Activator for Alzheimer’s Disease Therapy1R41AG058364-01 · under PA-16-303 | LI, YANGMEI | BRILLIANT BIOSCIENCES, INC., FL | $224,997 | ZRG1 |
| 2018 | Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)1R41HL140673-01A1 | HOFFMAN, STANLEY R | LUNG THERAPEUTICS, INC., TX | $224,997 | ZRG1 |
| 2018 | Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors1R41CA224652-01 · under PA-16-303 | HUANGPU, JUN | PANACISE BIO, INC., NC | $224,991 | ZRG1 |
| 2018 | Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS1R41HL140741-01 · under PA-16-303 | GARCIA, JOE G. N. | RESTORE THERAPEUTICS, LLC, AZ | $224,984 | ZRG1 |
| 2018 | Oxidation-resistant Anti-protease Therapy1R42HL140670-01 · under PA-16-303 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $224,967 | ZRG1 |
| 2018 | Development of a Point of Care Diagnostic Screening test for Kawasaki disease1R41HD093473-01A1 | JOHNSON, RAYMOND MORRIS | L2 DIAGNOSTICS, LLC, CT | $224,963 | ZRG1 |
| 2018 | Interventions to Improve Reproductive Health among Adolescents1R41HD094406-01 · under PA-16-303 | CHINMAN, MATTHEWFIRPO-TRIPLETT, REGINA | DFUSION, INC., CA | $224,957 | ZRG1 |
| 2018 | A ratcheting prosthetic partial finger using advanced rapid manufacturing technology1R41HD096942-01 | SLIKER, LEVIN | POINT DESIGNS, LLC, CO | $224,952 | ZRG1 |
| 2018 | Dual Tack Mesh Fixation System: Creation of a Mesh Fixation System for Hernia Treatment and Prevention1R41GM130213-01 | FISCHER, JOHN PATRICK | PARADIGM SURGICAL, LLC, PA | $224,946 | ZRG1 |
| 2018 | Furan fatty acids (FuFAs) as the active components of fish oils and omega-3 fatty acid products1R43AT009806-01A1 | CHANG, FEI | FURANICA, INC., PA | $224,944 | ZRG1 |
| 2018 | An integrated neural network analysis and video microscopy platform for fully automated particle tracking1R41GM130202-01 | LAI, SAMUEL | AI TRACKING SOLUTIONS, LLC, NC | $224,894 | ZRG1 |
| 2018 | eCPAT: Advancing public park information and technology resources to diverse audiences for healthy communities1R41CA217471-01A1 | KACZYNSKI, ANDREW | ENQ, LLC, SC | $224,843 | ZRG1 |
| 2018 | Imaging Biomarkers of Severe Respiratory Infections in Premature Infants1R41HL145669-01A1 | ENQUOBAHRIE, ANDINET ASMAMAWLINGURARU, MARIUS GEORGENINO, GUSTAVO | KITWARE, INC., NY | $224,812 | ZRG1 |
| 2018 | Developing a novel platform for rapid identification of drug targets and anti-targets1R41TR002293-01A1 | AL-ALI, HASSANSCHATZ, JONATHAN H | TRUVITECH, LLC, FL | $224,804 | ZRG1 |
| 2018 | Evaluating Synthetic Biology Produced Triterpene Oils in Adjuvant Formulations1R41AI141060-01 | CHAPPELL, JOE | ENEPRET, INC., KY | $224,703 | ZRG1 |
| 2018 | An unique patient population for clinical trials against noise-induced hearing loss1R41DC017406-01 | BAO, JIANXIN | GATEWAY BIOTECHNOLOGY, INC., MO | $224,700 | ZRG1 |
| 2018 | Enzymatic synthesis of heparin sulfate and chondroitin sulfate1R42GM128484-01 | XU, YONGMEI | GLYCAN THERAPEUTICS CORPORATION, NC | $224,650 | ZRG1 |
| 2018 | Double Chimeric Peptide Vaccine Feasible for Human Use that Protects against Disseminated Candidiasis caused by medically important Candida species1R41AI138722-01A1 | XIN, HONG | AUTOIMMUNE TECHNOLOGIES, LLC, LA | $224,645 | ZRG1 |
| 2018 | Reopening the Central Airway With Needle-Size Tentacle Manipulators1R41HL140709-01 · under PA-16-303 | WEBSTER, ROBERT JAMES | VIRTUOSO SURGICAL, INC., TN | $224,598 | ZRG1 |
| 2018 | TAPS-ESP: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use - Electronic Spanish Platform: Technologies to Increase Screening in Primary Care to Reduce Behavioral Health Disparities1R41MD012782-01 | SANCHEZ, KATHERINE | COG ANALYTICS, LLC, MD | $224,579 | ZRG1 |
| 2018 | System-independent quantitative cardiac CT perfusion1R41HL144271-01 | WILSON, DAVID LYNN | BIOINVISION, INC., OH | $224,240 | ZRG1 |
| 2018 | Veristride STEP-R: an interactive verbal/auditory gait trainer1R41NR018314-01 | BAMBERG, STACY J. MORRIS | VERISTRIDE, INC., UT | $224,226 | ZRG1 |
| 2018 | Technology for Non-invasive High-throughput Breath Tracking in Rodents1R41HL142489-01 | O'HARA, BRUCE FREDERICK | SIGNAL SOLUTIONS, LLC, KY | $223,940 | ZRG1 |
| 2018 | Tissue Oxygenation in Small Retinal Vessels1R41EY028499-01A1 | ELSNER, ANN E | AEON IMAGING, LLC, IN | $223,898 | ZRG1 |
| 2018 | Improving the Design of CRISPR/Cas9 Knockout Assays1R41GM126682-01A1 | LIU, WEIJUNWANG, XIAOWEI | NAWGEN, LLC, IL | $223,896 | ZRG1 |
| 2018 | Developing novel combination therapies for HSV genital infection.1R41AI134187-01A1 | MORRISON, LYNDA A.ROGERS, BRUCE LEE | CASTERBRIDGE PHARMACEUTICALS, INC., MA | $223,895 | ZRG1 |
| 2018 | 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)1R41HL139290-01A1 · under PA-16-303 | WEST, KARL | CENTERLINE BIOMEDICAL, INC., OH | $223,868 | ZRG1 |
| 2018 | Generating sandwich assays through MegaSTAR1R41TR002283-01A1 | KAY, BRIAN KENNETH | TANGO BIOSCIENCES, INC., IL | $223,556 | ZRG1 |
| 2018 | MtLDL detection to diagnose childhood tuberculosis1R41AI136071-01 · under PA-16-303 | SAMPSON, NICOLE S | CHRONUS PHARMACEUTICALS, INC., NY | $223,406 | ZRG1 |
| 2018 | Amelioration of rhinovirus induced asthma exacerbations by serpin B11R41AI141068-01 | BROIDE, DAVID HPEMBERTON, PHILIP | SERPLUS TECHNOLOGY, LLC, CA | $223,334 | ZRG1 |
| 2018 | Artificial Salivary Gland Dental Implant1R41DE028217-01 | KELLY, JOHN ROBERT | ORAL FLUID DYNAMICS, LLC, CT | $223,315 | ZRG1 |
| 2018 | Farnesol as Novel Treatment in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)1R41NS107057-01 | GIBSON, K MICHAELMCCONNELL, ALICEROULLET, JEAN-BAPTISTE O | SPERAGEN, INC., TX | $223,095 | ZRG1 |
| 2018 | In Silico Identification of Novel GHB Receptor Ligands for SSADH Deficiency, a Disorder of GABA Metabolism1R41NS107099-01 | MCCONNELL, ALICE | SPERAGEN, INC., TX | $223,038 | ZRG1 |
| 2018 | staRt: Enhancing speech treatment with smartphone-delivered biofeedback1R41DC016778-01 · under PA-16-303 | MCALLISTER, TARA | GIRLFRIENDS LABS, LLC, NY | $222,939 | ZRG1 |
| 2018 | Quantitative Magnetic Resonance Imaging Phantoms1R41EB025729-01A1 | HERNANDO, DIEGO | CALIMETRIX, LLC, WI | $222,758 | ZRG1 |
| 2018 | Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance1R41HL144143-01 | BREUER, CHRISTOPHER KANE | LYST THERAPEUTICS, LLC, OH | $222,703 | ZRG1 |
| 2018 | Design of Protease Stable Therapeutic Peptides by Non-Perturbative Modification1R41GM130257-01 | KUMAR, KRISHNA | VELUM, INC., MA | $222,678 | ZRG1 |
| 2018 | Novel treatment for DIC1R41HL135942-01A1 | CRUZ, MIGUEL ANGEL | A2 THERAPEUTICS, INC., TX | $222,472 | ZRG1 |
| 2018 | Quantitative Biotherapeutic Particle Characterization via Deep Neural Networks1R41GM130513-01A1 | CALDERON, CHRISTOPHER PETERRANDOLPH, THEODORE W | URSA ANALYTICS, INC., CO | $222,381 | ZRG1 |
| 2018 | LemurDx - Objectivity, precision, and clinical utility in hyperactivity measurement for childhood ADHD using smartwatches and machine learning algorithms.1R41MH119644-01 | GOEL, MAYANKLINDHIEM, OLIVER JAMESSHAABAN, SAMI | NURELM E-BUSINESS SOFTWARE, PA | $221,917 | ZRG1 |
| 2018 | Non-Metal PN Scavenger/Decomposition Catalysts for Treatment of Migraine1R41NS107058-01 | DUSSOR, GREGORY O | CERSCI THERAPEUTICS, INC., TX | $221,823 | ZRG1 |
| 2018 | Reprogrammed T Cells to prevent graft versus host disease1R41AI136755-01A1 · under PA-16-303 | BELLUCCI, JOSEPH J | ELEMENT GENOMICS, INC., NC | $221,507 | ZRG1 |
| 2018 | PET Imaging Agent for Myocardial Infarction1R41HL140919-01A1 | AWASTHI, VIBHUDUTTA | HEXAKIT, INC., OK | $221,173 | ZRG1 |
| 2018 | Wireless Implantable Neural Recording Device1R41NS107142-01A1 | GHAFFARI, ROOZBEH | NEUROLUX, INC., IL | $220,091 | ZRG1 |
| 2018 | Small Molecule Anti-Inflammatories for Ocular Graft Versus Host Disease1R41EY029185-01 | PEREZ, VICTOR L | EYEDESIS BIOSCIENCES, LLC, NC | $218,692 | ZRG1 |
| 2018 | Brillouin optical eye scanner prototypes for commercialization1R41EY028820-01A1 | CHERNYAK, DIMITRIYUN, SEOK-HYUN ANDY | INTELON OPTICS, INC., MA | $218,094 | ZRG1 |
| 2018 | Exploration of Low-Cost Long-Timescale Free Energy Perturbations on FPGAs1R41GM128533-01 | HERBORDT, MARTIN C | SILICON THERAPEUTICS, MA | $217,844 | ZRG1 |
| 2018 | Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease1R42AG058333-01 · under PA-16-303 | SOTO, CLAUDIOVOLLRATH, BEN | AMPRION, INC., CA | $217,647 | ZRG1 |
| 2018 | A momentum-enabled treadling methodology to improve gait and enhance mobility in patients with peripheral arterial disease1R41AG060764-01 | HAND, RICHARD ALAN | TREADWELL CORPORATION, NC | $216,521 | ZRG1 |
| 2018 | Automated Contingency Management System for Reduction of Alcohol Use1R41AA026793-01 | JOHNSON, RON KIMBERLYMCDONELL, MICHAEL GMCPHERSON, STERLING M | MANAGED HEALTH CONNECTIONS, LLC, WA | $215,954 | ZRG1 |
| 2018 | Catheter Based Cardiovascular Device Retrieval System1R41HL139309-01A1 | GORMAN, JOSEPH H | ONOCOR, LLC, PA | $213,823 | ZRG1 |
| 2018 | A Novel Therapeutic that Harnesses MIcrotubules to Enhance Corneal Wound Healing Following an Alkaline Burn1R41EY029176-01 | CHUCK, ROY SDEY, ABHINAVZHANG, CHENG | MICROCURES, INC., CA | $213,405 | ZRG1 |
| 2018 | C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under-Served College Population1R42AA026788-01A1 | BOCK, BETH CDEUTSCH, CHRISTOPHER | LIVE INSPIRED, LLC, DC | $211,856 | ZRG1 |
| 2018 | A novel PEDF peptide mimetic for diabetic retinopathy1R41EY029192-01 | WEI, JI-YE | SKYRAN BIOLOGICS, INC., PA | $204,762 | ZRG1 |
| 2018 | Smart Sensor Bandage for Ulcer Monitoring1R41NR018126-01 | KIM, CHANG-SOOSTOECKER, WILLIAM V | STOECKER & ASSOCIATES, MO | $202,226 | ZRG1 |
| 2018 | Insightful Surgical Vision Technology (ISVision) for intelligent real-time display of anatomic, physiologic, and pathologic information in surgery1R41EB026402-01A1 | KIM, PETER CW | ACTIV SURGICAL, INC, MA | $200,769 | ZRG1 |
| 2018 | An Engineered Nanoimmunotherapy for Melanoma1R41CA217294-01A1 · under PA-16-303 | FERNANDES, ROHANSWEENEY, ELIZABETH EVILLAGRA, ALEJANDRO V | IMMUNOBLUE, LLC, MD | $200,001 | ZRG1 |
| 2018 | A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices1R41HL137519-01A1 | BRUNNER, GLENNLING, JIAN | N8 MEDICAL, INC., OH | $200,000 | ZRG1 |
| 2018 | Commercialization of a Rapid Blood Test for Traumatic Brain Injury1R41NS102118-01A1 · under PA-16-303 | LOVELL, MARK ANTHONY | FAWKES BIOTECHNOLOGY, LLC, KY | $197,824 | ZRG1 |
| 2018 | Formation and Structural Property Relationships of a Tetracalcium Phosphate Bone Adhesive Biomaterial1R41AG060881-01A1 | HESS, BRIAN | REVBIO, INC., MA | $197,470 | ZRG1 |
| 2018 | The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy1R41DA044894-01A1 · under PA-16-303 | TOLL, LAWRENCE R | PHOENIX PHARMALABS, INC., UT | $186,687 | ZRG1 |
| 2018 | An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward1R41DA047186-01 | ELSOHLY, MAHMOUD AFREEMAN, KEVIN B. | ELSOHLY LABORATORIES, INC., MS | $180,830 | ZRG1 |
| 2018 | Noninvasive Monitoring of Total Hemoglobin Concentration in Neonates1R41HD094542-01A1 | RANDALL, GRAHAM | NONINVASIX, INC., TX | $179,722 | ZRG1 |
| 2018 | Numeric Expansion of CD-19 Specific T cells in Magnetic 3D Culture1R41AI136225-01 · under PA-16-303 | NAJJAR, AMER MTSENG, HUBERT | NANO3D BIOSCIENCES, INC., TX | $175,849 | ZRG1 |
| 2018 | Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation1R41CA232805-01 | KANAAN, SAMI BARNA | CHIMEROCYTE, INC., WA | $173,566 | ZRG1 |
| 2018 | The Novel Biopsy Needle Design and Delivery System to Minimize Needle Deflection and Optimize Needle Positioning to Improve Lesion Sampling Accuracy Using a Co-registered MRI/US Fusion Biopsy Platform1R41CA228877-01 | MONTGOMERY, JEFFREY SCOTT | PRODEVICE MEDICAL SUPPLIES AND EQUIPMENT, MI | $172,437 | ZRG1 |
| 2018 | Preclinical Development of 2nd Generation HIV Maturation Inhibitors1R41GM132683-01A1 | WILD, CARL | DFH PHARMA, INC., MD | $171,475 | ADDT |
| 2018 | Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial1R41HD094398-01 · under PA-16-303 | BERGHELLA, VINCENZO | ELM TREE MEDICAL INC., CA | $168,683 | ZRG1 |
| 2018 | Developing an efficient E-cigarette aerosol generation and exposure system for rodent models with aerosol characteristics equivalent to those inhaled by E-cigarette users1R41DA044788-01 · under PA-16-303 | KEWEKORDES, JOSEFSHAO, XUESI MAX | AUTOMATE SCIENTIFIC, INC., CA | $150,000 | ZRG1 |
| 2018 | Development of a low cost point-of-care device for rapid pathogen detection1R41AI141290-01 | LECLAIR, TIMOTHY | ELECTRONUCLEICS, INC., CA | $150,000 | ZRG1 |
| 2018 | Development of fully integrated electrochemical device for detecting metals in biological fluids1R41ES029873-01 | HILL, JAMES CURTISRUSINEK, CORY ALLEN | BIOANALYTICAL SYSTEMS, INC. (BASI), IN | $149,999 | ZRG1 |
| 2018 | Sonomyographic Control of Fiber-Optically Sensorized Prosthetic Fingers for Graded Force Actuation1R41NS107149-01A1 | BLACK, RICHARD J | INTELLIGENT FIBER OPTIC SYSTEMS CORP, CA | $149,990 | ZRG1 |
| 2018 | Compact Navigation System for CT-guided Needle Interventions1UT1CA224886-01A1 | TSE, TSZ HO | 3T TECHNOLOGIES, LLC, GA | $149,927 | ZRG1 |
| 2018 | Development and Validation of a Physical Anatomic Model for Surgical TrainingUsing 3D Printing Technology1R41EB026358-01A1 | GHAZI, AHMEDSTONE, JONATHAN JAY | SIMULATED INANIMATE MODELS, LLC, NY | $149,812 | ZRG1 |
| 2018 | Targeting the host response to limit infection by intracellular bacterial pathogens1R41AI141302-01 | LANNIGAN, DEBORAH | BLUE RIDGE BIOSCIENCES, LLC, VA | $148,836 | ZRG1 |
| 2018 | Non-Opiate Topical Formulations for Treating Pain Associated with Molar Extractions1R41DE028208-01 | JAY, MICHAEL | ARCATO LABORATORIES, INC., NC | $145,566 | ZRG1 |
| 2018 | Novel Home-Based and Low-Cost ECG Device for periodic evaluation of the presence of atrial fibrillation1R42NR018316-01A1 | COUDERC, JEAN-PHILIPPE Y | GLOBAL INSTRUMENTATION, LLC, NY | $136,516 | ZRG1 |
| 2018 | Portable Liquid Chromatograph for Point-of-Care Monitoring of Illicit Substances1R41DA045382-01A1 | GRINIAS, JAMES PTOLLEY, LUKE | AXCEND, LLC, UT | $135,024 | ZRG1 |
| 2018 | Mobile Support to Improve Recovery and Treatment Court Outcomes1R41DA046268-01A1 | FOSTER, ROBERTJENNINGS, ERNESTINE G | LIVE INSPIRED, LLC, DC | $122,108 | ZRG1 |
| 2017 | Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF25232R42CA192656-02A1 · under PA-16-303 | MORALES, GUILLERMO A | SIGNALRX PHARMACEUTICALS, INC., GA | $1,320,558 | ZRG1 |
| 2017 | An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents2R42HD088317-02 · under PA-16-303 | FIELLIN, LYNN ELIZABETHSCHELL, JESSE | SCHELL GAMES, LLC, PA | $1,100,650 | ZRG1 |
| 2017 | Peripheral FAAH as a target for novel analgesics2R42DA033683-02A1 · under PA-14-072 | PIOMELLI, DANIELE | ANTEANA THERAPEUTICS, INC., CA | $1,100,244 | ZRG1 |
| 2017 | Urine Diagnostics for Aspergillosis2R42AI115866-02A1 · under PA-16-303 | MARR, KIEREN A. | PEARL DIAGNOSTICS, INC., MD | $1,004,193 | ZRG1 |
| 2017 | Validation of Novel Therapeutic Approach for Cryptococcal Meningitis2R42AI120304-02 · under PA-15-270 | LAD, SHIVANAND PMCCABE, AARON RICHARD | MINNETRONIX, INC., MN | $1,000,000 | ZRG1 |
Showing the 200 most recent of 910 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.